To Get Full Access :

NCE-1 Intelligence & Market Opportunity

Gomekli

Mirdametinib
Anticancer
Oral Capsule And Oral Tablet, For Suspension

Gomekli treats adults and children (≥2 years) with NF1-related plexiform neurofibromas that can’t be fully removed. It inhibits MEK enzymes to slow tumor growth and reduce tumor size.

Approval Date
11-Feb-25
NCE-1 Date
11-Feb-29
NCE Date
11-Feb-30
Commercial snapshot

Market performance & projections

Revenue ($M)
82
CAGR (%)
75.56%
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
186
2027
385
2028
587
2029
779
2030
927
2031
1,054
2032
983
Molecule profile

Details & specifications

Molecule
Mirdametinib
Innovator
SPRINGWORKS THERAPEUTICS INC
Dosage Form
Oral Capsule And Oral Tablet, For Suspension
Strength
1 mg and 2 mg
Therapeutic Category
Anticancer
Usage
To treat neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?